Response Genetics, Inc. (Response Genetics) announced its plan to triple the size of its sales force in response to higher demand for its ResponseDx genetic testing services, which initially focused on the California market, to begin serving most major national markets. Response Genetics has sold more than 500 of its ResponseDx: Lung and ResponseDx: Colon tests since their launch in September 2008.

The company has also experienced a reorder rate of over 90%.

“The promise of personalized medicine is quickly becoming a reality for patients with lung and colon cancer through diagnostic tests such as those developed by Response Genetics,” said Heinz-Josef Lenz, M.D., a professor of medicine at USC’s Keck School of Medicine, as well as the scientific director of the Cancer Genetics Unit and associate director of the Gastrointestinal Oncology Program at the USC Norris Comprehensive Cancer Center. “ResponseDX(TM) tests are quickly becoming part of routine testing to increase efficacy for our patients.”

“We are encouraged by the early sales and rapid initial adoption of our first commercially available genetic tests — ResponseDX: Lung(TM) and ResponseDX: Colon(TM) — and are adjusting our sales strategy accordingly to meet this higher demand,” said Kathleen Danenberg, Response Genetics’ president and chief executive officer. “We attribute this in part to a greater market understanding and acceptance of genetic testing for cancer patients as well as our successful reimbursement strategy.”